Key Art Banner

Checklist: Scientific Strides To Beat COVID-19

As they search for an antibody to coronavirus, Eli Lilly begins their second clinical trial.
Posted on Jun 23, 2020 | 04:25pm
Spotlight | Brought to you by Watch

Eli Lilly and Company will soon start dosing healthy U.S. study participants with a potential neutralizing antibody designed to fight COVID-19, as they begin their Phase 1 clinical trial to assess the hoped-for antibody's safety. Referred to as JS016, the antibody is being co-developed with Junshi Biosciences, who recently dosed their first healthy volunteer and are leading development in greater China; while Lilly has exclusive rights in the rest of the world.

JSO16 is actually Lilly's second neutralizing antibody to begin clinical trials--their first, LY-CoV555, is currently being tested in patients who are hospitalized with COVID-19. "The best path to learn more about the potential for neutralizing antibodies, either as monotherapy or in combination, is through carefully controlled randomized trials," says Daniel Skovronsky, M.D., Ph.D., Lilly's chief scientific officer and president of Lilly Research Laboratories. "We look forward to the results of such trials in the coming months."

Photo Credit: Motortion/Getty Images.